{"query":"Heron Therapeutics Craig Collard acute care therapeutics news","follow_up_questions":null,"answer":null,"images":[],"results":[{"url":"https://www.prnewswire.com/news-releases/heron-therapeutics-announces-new-ceo-and-board-chairman-301787928.html","title":"Heron Therapeutics Announces New CEO and Board Chairman","content":"(NASDAQ: HRTX) (\"Heron\" or the \"Company\"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced the appointment of Craig Collard as Chief Executive Officer (CEO), effective today. Mr. Collard most recently served as the Chief Executive Officer of Veloxis Pharmaceutics A/S (now Veloxis Pharmaceuticals Inc., \"Veloxis\") before it was acquired by Asahi Kasei Corp, a transplant-focused pharmaceutical company with its principal office in Cary, North Carolina, from 2015 to December 2021, and remains on the Veloxis board of advisors. Prior to joining Veloxis, Mr. Collard served as the Chief Executive Officer and the Chairman of the Board of Directors of Cornerstone Therapeutics, Inc., a pharmaceutical company (\"Cornerstone\"), from 2011 until it was acquired by Chiesi Farmaceutici S.p.A. in 2014.","score":0.8296166,"raw_content":null},{"url":"https://seekingalpha.com/news/4514857-heron-therapeutics-outlines-153m-163m-net-revenue-target-as-acute-care-momentum-accelerates","title":"Heron Therapeutics outlines $153M–$163M net revenue target as ...","content":"Collard described new acute care initiatives, including the CrossLink Ignite program, launch of the VAN (200-milligram vial access needle)","score":0.8088086,"raw_content":null},{"url":"https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-preliminary-unaudited-q4-and-full","title":"ZYNRELEF® Largest Contributor to Q4 Growth - Heron Therapeutics","content":"[Skip to main navigation](https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-preliminary-unaudited-q4-and-full#main-menu). [Skip to content](https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-preliminary-unaudited-q4-and-full#main). [![Image 1: Heron Therapeutics Logo](https://ir.herontx.com/sites/g/files/knoqqb57786/themes/site/nir_pid1264/dist/images/heron-logo.svg)](https://www.herontx.com/). *   [Product Portfolio](https://www.herontx.com/product-portfolio/). *   [SUSTOL®](https://www.herontx.com/product-portfolio/sustol/). *   [CINVANTI®](https://www.herontx.com/product-portfolio/cinvanti/). *   [ZYNRELEF™](https://www.herontx.com/product-portfolio/zynrelef/). *   [APONVIE™](https://www.herontx.com/product-portfolio/aponvie/). *   [Our Focus](https://www.herontx.com/patients/). *   [Acute Care](https://www.herontx.com/patients/acute-care/). *   [Oncology Care](https://www.herontx.com/patients/oncology/). *   [About](https://www.herontx.com/about/). *   [Contact Us](https://www.herontx.com/about/contact/). [« Back](https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-preliminary-unaudited-q4-and-full#). Forward-looking statements include, among others, statements we make regarding the estimated preliminary financial results referred to above, the potential market opportunities for ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL®; revenue, adjusted EBITDA and other financial guidance provided by the Company; interim financial data or prescription data, which may not necessarily be indicative of quarterly or annual results; the potential additional market opportunity for the expanded U.S. label for ZYNRELEF or inclusion of ZYNRELEF under the OPPS and the ASC payment system or launch of the ZYNRELEF VAN; our ability to establish and maintain successful commercial arrangements like our co-promotion agreement with Crosslink Network, LLC; the outcome of the Company's pending patent litigations, including potential appeals of any verdicts and the settlement described herein; whether the Company is required to write-off any additional inventory in the future; the expected future balances of Heron's cash, cash equivalents and short-term investments; the expected duration over which Heron's cash, cash equivalents and short-term investments balances will fund its operations and the risk that future equity financings may be needed; the terms and conditions, completion of the refinancing transactions, and the anticipated proceeds and use of proceeds of the refinancing transactions; any inability or delay in achieving profitability, including as a result of regulatory developments and policy changes in the U.S. and other jurisdictions. [Print Page](https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-preliminary-unaudited-q4-and-full#). [![Image 3: Heron Therapeutics Logo](https://ir.herontx.com/sites/g/files/knoqqb57786/themes/site/nir_pid1264/dist/images/heron-logo.svg)](https://www.herontx.com/). [844-HERON11 (844-437-6611)](tel:844-437-6611)[heronmc@eversana.com](https://ir.herontx.com/news-releases/news-release-details/heronmc@eversana.com).","score":0.7447496,"raw_content":null},{"url":"https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-appointment-thomas-cusack-board","title":"Heron Therapeutics Announces Appointment of Thomas Cusack to ...","content":"“We are pleased to welcome Tom to Heron's Board of Directors,” said Craig Collard , Chief Executive Officer of Heron. ... care for acute care and","score":0.7407191,"raw_content":null},{"url":"https://herontherapeutics.gcs-web.com/board-member/steve-davis","title":"Craig Collard - Board Member - Heron Therapeutics","content":"Prior to joining Veloxis, Mr. Collard served as the Chief Executive Officer and the Chairman of the Board of Directors of Cornerstone Therapeutics, Inc., a pharmaceutical company (“Cornerstone”), from 2011 until it was acquired by Chiesi Farmaceutici S.p.A. in 2014. Mr. Collard also served as Cornerstone’s Interim Chief Financial Officer, from 2010 to 2011, and as its President, from 2008 to 2011. Mr. Collard served as the Founder, President and Chief Executive Officer of Cornerstone BioPharma Inc. Prior to that, Mr. Collard served as President and Chief Executive Officer of Carolina Pharmaceuticals, Inc., a specialty pharmaceutical company that he founded in 2003. From 2002 to 2003, Mr. Collard served as Vice President of Sales for Verum Pharmaceuticals, Inc., a specialty pharmaceutical company. Mr. Collard currently serves on the board of directors of Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company in Santa Monica, California developing therapies to treat substance use disorders and drug overdoses, since October 2018 and as Chairman, since January 2021.","score":0.6479992,"raw_content":null}],"response_time":0.78,"request_id":"de9276b5-640d-4670-9eeb-b6d80395aa62"}